Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study
Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Novartis Pharma AG Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1 40.7% of…
Roche’s prasinezumab shows promise on PD progression with five-year data
At the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, Roche showcased new…
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk…
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk…
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and…
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
F. Hoffmann-La Roche Ltd Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk…